Is fenofibrate the missing piece in COVID-19 management?

References

• El ZME, Järhult JD. From SARS to COVID-19: A previously unknown SARS-CoV-2 virus of pandemic potential infecting humans – call for a one health approach. One Health. 2020;9:100124.
   Web of Science ®Google Scholar
• Rajgor DD, Lee MH, Archuleta S, et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 Published Online 2020 Mar 27. DOI:10.1016/S1473-3099(20)30244-9
   Web of Science ®Google Scholar
• Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020;395(10229):1014–1015.
   PubMed Web of Science ®Google Scholar
• Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198.
   PubMed Web of Science ®Google Scholar
• Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12(372):1–17.
   Google Scholar
• Zheng C, Wang J, Guo H, et al. Risk-adapted treatment strategy for COVID-19 patients. Int J Infect Dis. 2020 Mar 27;S1201-9712(20):30179–X. Epub ahead of print.
   Google Scholar
• Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92(5):479–490.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.. Epub 2020 Mar 16.
   PubMed Web of Science ®Google Scholar
• Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. Biomed Pharmacother. 2020;128:110267.
   PubMed Web of Science ®Google Scholar
• Noonan JE, Jenkins AJ, Ma JX, et al. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013;62(12):3968–3975.
   PubMed Web of Science ®Google Scholar
• Prasad GS, Govardhan P, Deepika G, et al. Anti-inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: in silico, in vitro, and in vivo studies. Inflammopharmacology. 2018;26(4):973–981.
   Web of Science ®Google Scholar
• Chan NN, Chow FC. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet. 2001;358(9295):1811.
   Google Scholar
• Ibarra-Lara L, Hong E, Soria-Castro E, et al. Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia. J Cardiovasc Pharmacol. 2012;60(4):323–334.
   Web of Science ®Google Scholar
• Pastick KA, Okafor EC, Lofgren SM, et al. Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis. 2020;7(4):ofaa130.
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2: 69.
   PubMed Web of Science ®Google Scholar
• Wösten-van Asperen RM, Bos AP, Bem RA, et al. Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome. Pediatr Crit Care Med. 2013;14(9):e438–41.
   Web of Science ®Google Scholar
• Yuan S. Statins may decrease the fatality rate of middle east respiratory syndrome infection. mBio. 2015;6(4):e01120.
   PubMed Web of Science ®Google Scholar
• Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. mBio. 2020;11:e00398–e00420.
   PubMed Web of Science ®Google Scholar
• Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol. 2011;107(7):1010–1018.e1.
   PubMed Web of Science ®Google Scholar
• Goto M. A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol. 2010;20(3):238–243.
   PubMed Web of Science ®Google Scholar
• Krysiak R, Gdula-Dymek A, Marek B, et al. The effect of hypolipidaemic treatment on monocyte release of proinflammatory cytokines in different age groups of patients with type 2 diabetes and atherogenic dyslipidaemia. Endokrynol Pol. 2016;67(2):190–196.
   Web of Science ®Google Scholar
• Sharma R, Mahajan M, Singh B, et al. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients. J Indian Med Assoc. 2006;104(9):492–494.
   Google Scholar
• Gordon EM, Figueroa DM, Barochia AV, et al. High-density lipoproteins and apolipoprotein A-I: potential new players in the prevention and treatment of lung disease. Front Pharmacol. 2016;7:323.
   Web of Science ®Google Scholar